Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
March 27, 2023 08:30 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced the presentation of three posters featuring preclinical data at the upcoming 2023 American...
Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium
November 29, 2022 08:30 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs)...
Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update
October 18, 2022 16:05 ET
|
Ambrx Biopharma Inc.
- Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway...
Ambrx Biopharma to Host Corporate Update Conference Call
October 11, 2022 16:05 ET
|
Ambrx Biopharma Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create...